The Effect of Liposomal Bupivacaine Erector Spinae Plane Block

Starting soon · Not applicable

Conditions studied: Liposome Bupivacaine, Erector Spinae Plane Block, Postoperative Analgesia, Randomized Controlled Trial

In brief

This is a single-center, randomized, controlled, double-blind clinical trial. A total of 148 patients undergoing elective open upper abdominal surgery will be included and randomly assigned 1:1 to receive ultrasound-guided erector spinae plane block with liposome bupivacaine plus bupivacaine hydrochloride or bupivacaine hydrochloride alone. The primary outcome is the AUC of resting pain scores from 0 to 72 hours postoperatively. This study aims to evaluate the analgesic efficacy and safety of liposome bupivacaine and provide a long-acting and safe postoperative analgesia strategy.

Key facts

Study ID

NCT07667439

Run by

Second Affiliated Hospital, Zhejiang University, School of Medicine

People needed

148

Starts

2026-07-01

Expected to finish

2027-02-05

Last updated by the study team

2026-06-25

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients scheduled for elective open upper abdominal surgery, including open liver, gastric and pancreatic surgery.
• Patients receiving general anesthesia with tracheal intubation.
• Aged from 18 to 80 years old.
• Patients with American Society of Anesthesiologists (ASA) physical status class Ⅰ-Ⅲ.
• Patients who can understand the trial content, are willing to strictly follow the clinical research protocol and complete the trial, and voluntarily sign the informed consent form.

You may not qualify if…

• Pregnant or lactating women.
• Patients complicated with severe primary diseases of the lung, liver, kidney, cardiovascular system and hematopoietic system.
• Bleeding tendency or coagulation dysfunction, defined as international normalized ratio (INR) ≥ 1.4, activated partial thromboplastin time > 38 s, or platelet count < 80×10⁹/L.
• Patients with aggravated cardiac diseases (complex congenital heart disease, heart failure and valvular disease) or pulmonary insufficiency.
• Skin infection at the puncture site for erector spinae plane block (ESPB).
• Previous history of neurological or psychiatric diseases, with inability to read, understand and communicate.
• Current obstructive or restrictive pulmonary disease.
• Patients with BMI greater than 30 kg/m².
• Drug abuse, long-term regular use of analgesics, or allergy to the study drugs.
• Patients who refuse to provide informed consent.
• Those enrolled in other randomized controlled trials simultaneously or with other conditions unsuitable for participation in this trial.

Where it is running

• the Second Affiliated Hospital, Zhejiang University School of Medicine — Hangzhou, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.